Related Experiment Video
Updated: Jul 20, 2026

Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
Infusion of platelets transiently reduces nucleoside overload in MNGIE
1Laboratori de Patologia Neuromuscular i Mitocondrial, Institut de Recerca Hospital Universitari Vall d'Hebron, Pg. Vall d'Hebron 119, 08035 Barcelona, Spain.
Abstract:
Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) is caused by thymidine phosphorylase (TP) deficiency, which leads to toxic accumulations of thymidine (dThd) and deoxyuridine (dUrd). In this work, we report that infusion of platelets from healthy donors to patients with MNGIE restored transiently circulating TP and reduced plasma dThd and dUrd levels, suggesting that treatments to achieve permanent restoration of circulating TP such as allogeneic stem cell transplantation or gene transfer might be therapeutic.
Insights
Platelet infusions temporarily restored thymidine phosphorylase (TP) in MNGIE patients, reducing toxic thymidine and deoxyuridine levels. This suggests stem cell or gene therapy could offer permanent TP restoration for MNGIE treatment.
Area of Science:
- Biochemistry
- Genetics
- Neuroscience
Background:
- Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) is a rare genetic disorder.
- It results from thymidine phosphorylase (TP) deficiency.
- This deficiency causes toxic buildup of thymidine (dThd) and deoxyuridine (dUrd).
Observation:
- Platelets contain functional thymidine phosphorylase (TP).
- Infusion of platelets from healthy donors was administered to MNGIE patients.
- Circulating TP levels and plasma dThd/dUrd concentrations were monitored.
Findings:
- Platelet infusion transiently restored TP activity in MNGIE patients.
- Plasma levels of toxic metabolites thymidine (dThd) and deoxyuridine (dUrd) were reduced.
- This indicates a functional transfer of TP via platelets.
Implications:
- Platelet therapy offers a potential temporary treatment for MNGIE.
- Strategies for permanent TP restoration, like stem cell transplantation or gene therapy, warrant further investigation.
- These findings open new avenues for managing MNGIE and related metabolic disorders.
Related Concept Videos
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Antiviral Nucleoside Inhibitors
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

